Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in HFpEF (Japan)
jRCT2080224096Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2018
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) comparing Dapagliflozin arm with Placebo arm (2 arms). Primary endpoint: Primary composite outcome. Started Oct 2018; status: completed.
02
Drugs
dapagliflozin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on jRCT2080224096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224096.